Phathom Pharmaceuticals (PHAT) announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. Narula most recently served as CFO at Intra-Cellular Therapies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom clarifies no reduction in lead shareholder’s ownership amid 13D filing
- Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Phathom Pharmaceuticals Reports Strong Q2 Growth
- Phathom Pharmaceuticals: Strong Buy Rating Driven by Robust Revenue Performance and Growth Potential
- Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)